Trichem Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 8.00 M
as on 24-10-2024
- Paid Up Capital ₹ 8.00 M
as on 24-10-2024
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 10.20 Cr
as on 24-10-2024
- Revenue -0.56%
(FY 2023)
- Profit -90.58%
(FY 2023)
- Ebitda -96.92%
(FY 2023)
- Net Worth 0.97%
(FY 2023)
- Total Assets 21.29%
(FY 2023)
About Trichem Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 8.00 M and a paid-up capital of Rs 8.00 M.
The company has closed loans amounting to ₹10.20 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Chetan Jain, Ramesh Jain, and Anand Soshte serve as directors at the Company.
- CIN/LLPIN
U24230MH2004PLC146573
- Company No.
146573
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
27 May 2004
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Trichem Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chetan Jain  | Director | 27-Aug-2004 | Current |
| Ramesh Jain | Director | 05-Jun-2009 | Current |
| Anand Soshte | Director | 12-Sep-2014 | Current |
Financial Performance of Trichem Lifesciences.
Trichem Lifesciences Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.56% decrease. The company also saw a substantial fall in profitability, with a 90.58% decrease in profit. The company's net worth moved up by a moderate rise of 0.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trichem Lifesciences?
In 2023, Trichem Lifesciences had a promoter holding of 99.97% and a public holding of 0.03%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Trichem Healthcare Private LimitedActive 20 years 2 monthsChetan Jain, Ramesh Jain and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Icici Bank Limited Creation Date: 27 Jul 2013 | ₹2.50 Cr | Satisfied |
Icici Bank Limited Creation Date: 06 Apr 2013 | ₹2.50 Cr | Satisfied |
The Saraswat Co-Operative Bank Ltd Creation Date: 19 Sep 2011 | ₹3.50 M | Satisfied |
How Many Employees Work at Trichem Lifesciences?
Unlock and access historical data on people associated with Trichem Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trichem Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trichem Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
